Synthesis, X-ray crystal structure and cytotoxicity of a new tetranuclear ruthenium arene complex by Noffke, A L et al.
1 
Synthesis, x-ray crystal structure and cytotoxicity of a new  
tetranuclear ruthenium arene complex 
Anna Louisa Noffke,[a] Melanie Bongartz,[a] Wim Wätjen,[b] Philip Böhler,[b] Bernhard 
Spingler[c],[‡] and Peter C. Kunz*[a] 
[a] Heinrich-Heine-Universität, Institut für Anorganische Chemie und Strukturchemie I, 
Düsseldorf, Universitätsstr. 1, D-40225 Düsseldorf, Germany, Fax: +49 211 8112873, Email: 
peter.kunz@uni-duesseldorf.de 
[b] Heinrich-Heine-Universität, Universitätsklinikum, Institut für Toxikologie, Düsseldorf, 
Universitätsstr. 1, D-40225 Düsseldorf, Germany 
[c] Anorganisch-Chemisches Institut, Universität Zürich-Irchel, Winterthurerstr. 190, CH-
8057 Zürich, Switzerland 
[‡] X-ray structure analysis. 
Keywords 
Imidazolylphosphanes, Phosphane Ligands, PN Ligands, Ruthenium 
Abstract 
The tetranuclear ruthenium arene compound [(cym)4Ru4(2)Cl6]Cl2 (3) (cym = η6-p-cymene, 2 
= 1,2-bis(di-N-methylimidazol-2-ylphosphino)ethane) was prepared and characterised by one 
and two dimensional NMR-techniques. Its cytotoxicity against four different cell lines was 
determined and, with an approximate IC50 of >100µM 3 can be regarded as non-toxic. Its 
partition coefficient in n-octanol/water (logD7.4) was also determined. The structure of 
complex 3 as well as of the related compound [(cym)2Ru2(4)Cl2]Cl2 (5) (4 = 1,2-bis(di-N-
methylimidazol-2-ylphosphino)ethane dioxide) were determined by single crystal structure 
analysis. Upon oxidation in protic solvents, ligand 2 shows P–C bond cleavage reactions to 
yield P,P’-bis(N-methylimidazol-2-yl)ethylene diphosphinic acid (6). 
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1. Introduction 
The development of new metal-based therapeutic agents is a growing field in both 
bioinorganic and bioorganometallic chemistry [1-3]. Within this research area, the concept of 
ruthenium-arene complexes of the general formula [(η6-arene)Ru(X)(Y)(Z)] as possible anti-
cancer drugs is by now well established [4-7] and has recently been reviewed [8]. The 
common structural motif found in these compounds is a “piano-stool” geometry of the 
ruthenium center, coordinated by one arene ligand as the “seat” and three other ligands that 
build the “legs”. Therein, X and Y can be either two monodentate ligands or one bidentate 
chelating ligand and Z usually is a leaving group. In recent years, especially compounds like 
the RAPTA complexes [9-11] have emerged as water-soluble examples in this class, bearing 
one water-soluble phosphane ligand. Enhancing the water solubility and tuning the 
compounds hydrophilic/hydrophobic balance is of great interest for the use as metallo-drug, 
because these features might be a means to control the biodistribution and -availability of the 
compound. Although examples for this concept can be found in gold phosphane complexes of 
the water soluble bis(dipyridylphosphino)ethane ligands [12-14], little is known about 
ruthenium arene complexes of these ligands. 
Therefore we aimed to prepare a ruthenium-arene P,P-chelate complex of the imidazolyl-
bisphosphine 1,2-bis(di-N-methylimidadol-2-ylphosphino)ethane (2-dimpeNMe, 2) that was 
recently developed in our group as a water-soluble diphos-type ligand [15]. The aspired 
monocationic complex [(cym)Ru(2)Cl]Cl (cym = η6-p-cymene) should be highly water 
soluble and of the described piano-stool geometry. Similar compounds, as for example the 
complex [(cym)Ru(dppe)Cl]Cl are known as efficient catalyst precursors for the 
hydrogenation of styrene in aqueous media [16].  
We herein present the results of this study, being synthesis, characterisation and X-ray crystal 
structure of a new ruthenium compound with four p-cymene ruthenium moieties that are of 
the piano-stool geometry. The water solubility and partition coefficient (logD7.4) of this new 
multi-core complex was determined, in order to assess its hydrophobic/hydrophilic behaviour. 
Furthermore, the cytotoxicity was tested against different normal and cancerous cell lines, 
since several examples can be also found for multinuclear ruthenium compounds to exhibit 
DNA binding or cytotoxoic effects on various cell lines [17-22]. 
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2. Experimental section 
2.1 Synthesis 
The compounds 2-dimpeNMe (2) and [(cym)Ru(en)Cl]Cl (7) were synthesized according to 
reported procedures [15,5]. All reactions were carried out in Schlenk tubes under an 
atmosphere of dry nitrogen using anhydrous solvents purified according to standard 
procedures. All chemicals were purchased from commercial sources and used as received. 1H, 
13C and 31P NMR spectra were recorded on a Bruker DRX 200 and Bruker DRX 500 
spectrometer. The 1H spectra were calibrated against the residual proton signal of the solvent 
as an internal reference (methanol-d4: δH = 3.31 ppm; D2O: δH = 4.79 ppm) while the 31P{1H} 
NMR spectra were referenced to external 85% H3PO4. The MALDI mass spectra were 
recorded on a Bruker Ultraflex MALDI-TOF mass spectrometer. The elemental composition 
of the compounds was determined with a Perkin Elmer Analysator 2400 at the Institut für 
Pharmazeutische und Medizinische Chemie, Heinrich-Heine Universität Düsseldorf. 
2.1.1 Synthesis of [(cym)4Ru4(2)Cl6]Cl2 (3) 
[(cym)Ru(µ-Cl)Cl]2 (1) (0.15 g, 0.25 mmol) and 2-dimpeNMe (2) (50 mg, 0.12 mmol) were 
dissolved in 50 mL of ethanol upon gentle heating. The red solution was stored for 20 hours at 
-18 °C before the volume was reduced to 20 mL. Addition of diethylether (80 mL) gave the 
product as a crude orange precipitate, which was isolated by filtration and dried in vacuo. 
Yield: 100 mg (50%). 1H NMR (200 MHz, 296 K, methanol-d4, see Figure 1 for atom 
labelling): δ = 1.33 (d, 12H, 3JH,H = 6.9 Hz, cym-iPr, n), 1.37 (d, 12H, 3JH,H = 6.9 Hz, cym-iPr, 
i), 1.44 (s, broad, 4H, PCH2CH2P, d), 1.82 (s, 6H, cym-Me, e), 1.95 (s, 6H, cym-Me, j), 2.89 
(m, 2H, cym-CH, m), 2.94 (m, 2H, cym-CH, h), 3.59 (s, broad, 12H, 2-dimpeNMe, c), 5.47 (d, 
4H, 3JH,H = 6.1 Hz, cym, f), 5.75 (d, 4H, 3JH,H = 6.1 Hz, cym, g), 5.77 (d, 4H, 3JH,H = 6.1 Hz, 
cym, k), 5.89 (d, 4H, 3JH,H = 6.1 Hz, cym, l), 7.74 (2-dimpeNMe, C5H, a), 7.79 (2-dimpeNMe, 
C4H, b). 13C{1H} NMR (125 MHz, 296 K, methanol-d4): δ = 17.9 (cym-Me, e), 18.2 (cym-
Me, j), 21.0 (cym-iPr, n), 21.9 (cym-iPr, i), 26.0 (PCH2CH2P, d), 30.7 (cym-CH, h), 31.4 
(cym-CH, m), 36.9 (2-dimpeNMe, c), 80.7 (cym, f), 86.3 (cym, g), 88.3 (cym, k), 90.2 (cym, l), 
128.7 (2-dimpeNMe, C5, a), 136.1 (2-dimpeNMe, C4, b). 31P{1H} NMR (81 MHz, 296 K, 
methanol-d4) δ = 34.3 (s). MALDI-TOF-MS: m/z (rel. int.) = 786 [M]2+ (100), 650 
[(cym)Ru(2)]+ (50). C58H80N8Cl8P2Ru4·8H2O (1783.30) calcd. C 39.0, N 6.3, H 5.4; found C 
38.7, H 5.2, N 6.1. LogD7.4 = - 0.48. 
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2.1.2 Synthesis of P,P’-bis(N-methylimidazol-2-yl)ethylene diphosphinic acid (6) 
50 mg (0.12 mmol) of 2 were dissolved in ethanol and stirred in air for one hour. H2O2 (30 % 
in H2O) was added dropwise and the solution was stirred at room temperature for another 8 
hours. A white precipitate formed, which was filtered off and dried in vacuo to yield 38 mg of 
a white solid. 1H NMR (200 MHz, D2O): δ = 1.93 – 1.99 (m, 4H, PCH2CH2P), 4.04 (s, 6H 
NMe), 7.51 (s, 2H, Him), 7.53 (s, 2H, Him). 13C{1H} NMR (125 MHz, 296 K, methanol-d4): δ 
= 24.7 (m, PCH2)2, 37.0 (s, NCH3), 121.2 (s, CH), 127.3 (s, CH). 31P{1H} NMR (81 MHz, 
D2O) δ = 17.0 (s). ESI–-MS m/z (rel. int.) = 317 (100) [M-H]-. MALDI-TOF-MS: m/z (rel. 
int.) = 318 (80) [M]+, 340 (100) [(M-H)+Na]+, 690 (75) [2M+3H2O]+. C10H22N4O4P2·3.5H2O 
(387.31): calcd. C 31.6, H 5.8, N 14.7; found C 31.4, H 5.5, N 14.6. 
2.2 Measurement of lipophilicity (logD) 
The octanol–water partition coefficient of compound 3 was determined using a shake-flask 
method. PBS buffered bi-destillated water (100 mL, phosphate buffer, c(PO43-) = 10 mM, 
c(NaCl) = 0.15 M, pH adjusted to 7.4 with HCl) and n-octanol (100 mL) were shaken 
together using a laboratory shaker (Perkin-Elmer), for 72 h to allow saturation of both phases. 
1 mg of 3 was mixed in 1 mL of aqueous and organic phase, respectively for 10 minutes using 
a laboratory vortexer. The resultant emulsion was centrifuged (3000 × g, 5 min) to separate 
the phases. The concentrations of 3 in the organic and aqueous phases were then determined 
using UV absorbance spectroscopy (230 nm). LogDpH was defined as the logarithm of the 
ratio of the concentrations of the complex in the organic and aqueous phases (logD = 
log{[3(org)]/[3(aq)]}); the value reported is the mean of three separate determinations. 
2.3  Cell culture 
Hct116 human colon carcinoma, Huh7 human hepatoma and H4IIE rat hepatoma cells were 
grown in Dulbecco´s modified Eagle´s medium (DMEM, GIBCO; Germany), A2780 human 
ovarian carcinoma cells were grown in RPMI cell culture medium; all media contained 10 % 
fetal calf serum (PAA Laboratories; Austria), penicillin (100 U / mL) and streptomycin (100 
µg / mL) at 5 % CO2 and 37 °C.  
2.4  Determination of cytotoxicity 
The effect of the compounds on cell viability was determined using the MTT assay [16]. Cells 
were plated on 96-multiwell plates (H4IIE, Hct116, Huh7 cells: 15.000 / well, A2780 cells: 
35.000 / well), allowed to attach for 24 h and then treated with different concentrations of the 
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substances for 24. After treatment medium was changed and cells were incubated for 30 min 
under cell culture conditions with 1 mg / mL MTT. Then the cells were lysed with 100 % 
dmso. The concentration of reduced MTT as a marker for cell viability was measured 
photometrically (560 nm) using a Wallace Victor2 1420 multilabel counter (Perkin-Elmer). 
2.5  Statistical analysis: 
All data were analyzed using one-way analysis of variance, followed by Bonferroni or Dunnet 
post hoc analysis to determine statistical significance. P values < 0.05 were considered 
statistically significant. The analysis was performed with GraphpadPrism 5.0c. 
2.6  Crystallography 
Crystallographic data were collected at 183(2) K on an Oxford Diffraction Xcalibur system 
with a Ruby detector using Mo Kα radiation (λ = 0.7107 Å) that was graphite-
monochromated. Suitable crystals were covered with oil (Infineum V8512, formerly known as 
Paratone N), mounted on top of a glass fibre and immediately transferred to the 
diffractometer. The program suite CrysAlisPro was used for data collection, semi-empirical 
absorption correction and data reduction [23]. Structures were solved with direct methods 
using SIR97 [24] and were refined by full-matrix least-squares methods on F2 with SHELXL-
97 [25]. The structures were checked for higher symmetry with help of the program Platon 
[26]. CCDC-789984 and -789985 contain the supplementary crystallographic data for this 
paper. These data can be obtained free of charge from The Cambridge Crystallographic Data 
Centre via www.ccdc.cam.ac.uk/data_request/cif.  
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3 Results and discussion 
3.1 Synthesis 
Recently, we reported on the synthesis of the novel multitopic diphos-type ligand 2-dimpeNMe 
(2) [15]. This ligand was designed to form complexes analogous to 1,2-
bis(diphenylphosphino)ethan (dppe) complexes but shows increased hydrophilicity and water-
solubility. The first attempts towards the favoured complex [(cym)Ru(2)Cl]Cl were carried 
out following a procedure described by Daguenet for [(cym)Ru(dppe)Cl]Cl [27]. However, 
using a metal-to-ligand ratio of 1:1 always resulted in precipitation of a light-red coloured 
solid which was insoluble in all common solvents and thus could not satisfyingly be 
characterised. Instead, other metal-to-ligand ratios were tested. Surprisingly, when 
[(cym)Ru(µ-Cl)Cl]2 (1) was reacted with the ligand 2-dimpeNMe (2) in 2 : 1 ratio, the solution 
stayed clear even upon cooling to -20 °C over night and the 31P{1H}-NMR spectrum showed 
a single singlet at 34 ppm. To elucidate the composition of this new species, which was later 
found to be 3, this shift was compared to the one for the chelate complex [(p-
cymene)Ru(dppe)Cl]Cl (δP = 50 ppm) [16] and the bridged complex [{(p-cymene)RuCl2}2(µ-
dppe)] (δP = 39 ppm) described by Coleman [28]. Due to the better analogy with the second 
complex the new species was suspected to contain p-cymene ruthenium moieties bridged by 
the diphos-ligand 2. 
 
 
Scheme 1. Synthesis of the four-core complex [(cym)4Ru4(2)Cl6]Cl2 
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3.2 Characterisation of 3 
Complex 3 was characterised by NMR techniques, mass spectrometry and single crystal 
structure determination. Full assignment of the 1H NMR signals could be achieved using the 
two-dimensional experiments H,H- and C,H-COSY. Furthermore, NOE contacts between the 
imidazolyl protons and their neighbouring p-cymene moieties were used to unambiguously 
confirm the assignment (Figure 1). 
 
 
Fig. 1. Assignment of 1H-NMR signals of 3 made by H,H COSY and NOESy-experiments. 
The 1H NMR spectrum of complex 3 (Figure 2) shows two sets of signals for the p-cymene 
protons due to two possible coordination modes of the 2-dimpeNMe ligand (2). For each set, 
NOE contacts with different imidazolyl protons were found: For the cymene protons e, f, g 
and i NOESy cross-peaks were only observed with the imidazole-H4 (a), whereas the 
imidazole-H5 (b) gave cross-peaks with the NMe protons (c) and the isopropyl protons (n) of 
the second set of cymene protons (j, k, l, n) only. Furthermore, the NMe protons (c) and the 
aromatic protons (l) show a NOE cross signal. This specific pattern of interactions can be 
correlated with the rigid arrangement of the imidazolyl moieties resulting from co-ordination. 
Due to the restrained flexibility in the chelate ring, the NMe-groups are fixed in one position 
and point away from the Ru2 atoms (Figure 3). Therefore, interactions with the corresponding 
p-cymene protons are not possible.  
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Fig. 2. 1H-NMR of compound 3 with assignments derived from 2D and NOE NMR 
experiments. 
When 3 was crystallised, additionally to the red coloured crystals of 3, a small orange 
coloured crystal was found. The structure of this by-product was also analysed by single 
crystal analysis. It turned out, that parts of the ligand 2 oxidised during the reaction to give the 
dioxide 4 (Scheme 2) which can only react towards the metal with the imidazolyl-nitrogen 
atoms. As a result, a two-core complex [{(cym)RuCl}2(µ-4)]Cl2 (5) had formed in which 4 
acts as a bridging bis-chelating ligand. 
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Scheme 2. Formation of the bridged complex [{(cym)RuCl}2(µ-4)]Cl2 (5) upon oxidation of 
the ligand 2 and decomposition of 2 to the betainic form of the phosphinic acid 6. 
3.3 Decomposition of 2-dimpeNMe (2) 
In order to establish a directed synthesis of complex 5 (Scheme 2), compound 2 was treated 
with different oxidising agents under various conditions. When 2-dimpeNMe (2) was treated 
with H2O2 in methanol or ethanol, after some time, a white solid precipitated from the 
reaction mixture. This compound gave a single singlet in the 31P{1H}-NMR spectrum at δP = 
18 ppm, which was also found upon oxidation of 2 in methanol under air as well as upon 
treatment of 2 with iodosobenzene in acetonitrile. Although this 31P NMR signal is shifted 74 
ppm compared to free 2 in methanol (δP = -52 ppm) [15], the precipitate was not characterised 
as the dioxide 4. One main reason for that is, that the protons of the ethylene bridge and the 
protons of the imidazolyl groups are found in a 4 : 4 ratio in the 1H NMR, which suggests the 
loss of two imidazolyl moieties per molecule. Since furthermore, the 31P{1H}-NMR shows 
two equivalent P atoms, the oxidation product is proposed to be P,P’-bis(N-methylimidazol-2-
yl)ethylene diphosphinic acid (6). Additional analytical data also agree with this suggestion, 
whereof especially the P=O valence vibration can be used as a probe for the proposed 
structure. The infrared spectrum showed an intense absorption band at 1204 cm-1, which was 
found to be the region of phosphinic acids [29]. This band is also characteristically broadened, 
which is thought to be a result of hydrogen bonding. Such a type of ligand decomposition by 
P–C cleavage reactions has already been observed in analogous monophosphanes. For 
example, tris(imidazol-2-yl)phosphane (2-TIPNH) decomposes to the corresponding 
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bis(imidazol-2-yl)phosphinic acid [30, 31], and a recent example from our group also shows 
this reactivity for bis(N-methylimidazol-2-yl)phenyl phosphane (2-BIPNMe) [32]. 
3.4 Solid state structures 
Red crystals of 3·0.8C4H10O were obtained by slow diffusion of diethyl ether into a 
methanolic solution. Compound 3·0.8C4H10O crystallises in the monoclinic space group C2/c. 
Additionally, an orange crystal of the by-product 5·4CH3OH was found, which crystallises in 
the triclinic space group P-1. The crystallographic data for both structures are summarised in 
table 1. Tables with all angles and bond lengths can be found in the supporting information 
(ESI). 
The coordination geometries of the ruthenium centers in 3 and 5 are best described as 
distorted octahedral. The metric parameters at the ruthenium atoms are within the range found 
in [(cym)Ru(C4H7N2)2Cl]Cl [33] and [(cym)Ru(bpm)Cl]Cl (bpm = bis(pyrazolyl)methane) 
[34] for Ru1 of 3 and 5 and compounds [(cym)Ru(PR3)Cl2] for Ru2 of 3 [35,36]. 
In the structures 3 and 5, the center of the ethylene group is localized on a two-fold rotational 
axis and a center of inversion respectively. In both structures, the ligand 2 adopts a transoid 
conformation with PCCP torsion angles of 153.5(3)° and 180.0°, respectively. The 
substituents at the phosphorus atoms, the (cym)Ru2Cl2 moieties in 3 and the O atoms in 5, 
point in opposite directions. In 5, the sterically demanding (cym)Ru1Cl substituents and the 
ethylene bridge adopt axial 1,4-positions, whereas in 3 both bulky (cym)Ru-moieties (at Ru1 
and Ru2) are at axial positions. This steric interaction leads to the less favoured envelope 
conformation of the six-membered chelate rings in 3, whereas in 5 a more boat-like 
conformation is found. In the structure of 3, the cymene ligand coordinated to Ru1 is 
disordered in a 6:4 ratio. Essentially two rotational confirmations of the cymene could be 
found. In order to model this disorder, restraints had to be applied and not all non-hydrogen 
atoms of the disordered cymene units could be refined anisotropically. 
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Fig. 3. Molecular structure of 3·0.8C4H10O. Uncoordinated counter ions, hydrogen atoms and 
solvent molecules are omitted for clarity, only one conformer is shown. The displacement 
ellipsoids are shown on a 50 % level. 
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Fig. 4. Molecular structure of 5·4CH3OH. Uncoordinated counter ions, hydrogen atoms and 
solvent molecules are omitted for clarity. The displacement ellipsoids are shown on a 50 % 
level. 
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Table 1 
Crystallographic data for compounds 3·0.8C4H10O and 5·4CH3OH. 
 3·0.8C4H10O 5·4CH3OH 
Empirical formula  C61.20H88Cl8N8O0.80P2Ru4 C42H68Cl4N8O6P2Ru2 
Formula weight  1698.42 1186.92 
Crystal system  Monoclinic Triclinic 
Space group  C2/c P-1 
a [Å]  22.6969(7)  8.7986(1)  
b [Å]  10.6605(4)  12.0206(2)  
c [Å]  28.364(1)  13.7090(2)  
 [°]  90 67.1764(14) 
 [°]  90.334(3) 86.2548(12) 
 [°]  90 72.8348(13) 
Volume [Å3]  6862.9(4)  1274.88(3)  
Z 4 1 
Density (calculated) [Mg/m3]  1.644  1.546  
Absorption coefficient [mm-1]  1.267 0.917 
Crystal size [mm3]  0.17 x 0.10 x 0.04  0.39 x 0.32 x 0.18  
Crystal description red needle orange plate 
Reflections collected 18375 58803 
Independent reflections 6884 [R(int) = 0.0770] 12331 [R(int) = 0.0235] 
Reflections observed 3799 11096 
Completeness to theta  98.0 % to 26.37°  99.8 % to 36.32°  
Max. and min. transmission 0.9511 and 0.6383 0.8523 and 0.7851 
Data / restraints / parameters 6884 / 153 / 423 12331 / 0 / 312 
Goodness-of-fit on F2 0.925 1.046 
Final R indices [I>2sigma(I)] R1 = 0.0517 
wR2 = 0.0896 
R1 = 0.0246 
wR2 = 0.0695 
R indices (all data) R1 = 0.1248 
wR2 = 0.1175 
R1 = 0.0288 
wR2 = 0.0708 
Largest diff. peak and hole [e.Å-3]  1.019 and -0.574 1.256 and -1.558 
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3.5 Solubility, distribution coefficient and cytotoxicity 
Despite the four p-cymene ligands, compound 3 is soluble in aqueous solutions, as can be 
seen from a solubility of 16 g/L in water. The water-solubility is also reflected by the 
distribution coefficient in n-octanol/water of logD7.4 = - 0.48. 
The cytotoxicity of compound 3 was determined in four different cell-lines using the MTT 
assay method. For comparison, the compound [(cym)Ru(en)Cl]Cl (7) (en = 1,2-
diamminoethane) was also introduced in the cell line studies [5]. Cell lines used were Hct116 
human colon carcinoma, Huh7 human hepatoma, H4IIE rat hepatoma and A2780 human 
ovarian carcinoma cells (cisplatin sensitive). As can be seen from Figure 5, compound 3 is 




Fig. 5. Cytotoxic effects of 3 and 7 at Hct116, Huh7, H4IIE and A2780 cells. Cells were 
treated with different concentrations of the substances for 24. After treatment cell viability 
was analysed using MTT assay. The concentration of reduced MTT as a marker for cell 
viability was measured photometrically. Values are means +/- standard deviation, n = 3, *: p < 
0.05 vs. control value, #: p < 0.05 vs. corresponding concentration of the other substance (3 
vs. 7). 
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Although the IC50 values for the tested compounds have not been determined for all cell lines 
in this test, the specific value for compound 3 is greater than 100µM which is simply 
concluded by the observed non-toxicity up to this value. For the cell lines H4IIE and Hct116 
the IC50 values have been determined to 705 and 393 µM, respectively. In comparison with 
other tetranuclear ruthenium-arene compounds, this value is particularly high. For example, 
rectangular shaped structures with bridging N- and O,O-ligands exhibit IC50 values between 4 
µM and 66 µM, whereof the lowest value lies in one range with cisplatin [20]. Equally high 
cytotoxicities are reached with hexanuclear ruthenium assemblies which can also function as 
hosts for smaller drug molecules [21]. Tetranuclear ruthenium compounds with dendritic 
structures that seem more similar to compound 3 show IC50 values of 40 µM which can still 
be regarded as active [19,22]. With an overall charge of 2+ complex 3 ranges between the 
charge-neutral dendrimers and the 4+ rectangular systems but its activity might still be limited 
by the possibilities to pass the cell membrane. 
4 Conclusion 
The new tetranuclear ruthenium arene complex 3 is readily available from the common 
precursor [(cym)Ru(µ-Cl)Cl]2 and the water-soluble multitopic diphos-type ligand 1,2-bis(di-
N-methylimidadol-2-ylphosphino)ethane (2-dimpeNMe, 2). In this compound, 2 unfurls truly 
multitopic qualities, as all six coordination sites, including the imidazolyl nitrogen atoms, are 
occupied by ruthenium. Interestingly, even though the nitrogen atoms are blocked, complex 3 
is still quite soluble in aqueous media. Its cytotoxic activity is, however, much lower than that 
of known tetranuclear compounds of the ruthenium arene family. Conclusively, 3 is 
particularly stable in aqueous solution. In contrast to this stability, the free ligand 2-dimpeNMe 
(2) undergoes P–C bond cleavage in protic solvents within a few hours. The loss of imidazolyl 
substituents is therein excellerated by addition of oxidising agents.  
5 References 
[1] Z. Guo, P.J. Sadler, Angew. Chem. 111 (1999) 1610–1630; Angew. Chem. Int. Ed. 38 
(1999) 1512–1531. 
[2] G. Jaouen (ed), Bioorganometallics, Wiley-VCH, Weinheim, 2006. 
[3] S.H. van Rijt, P.J. Sadler, Drug Discovery Today 14 (2009) 1089–1097. 
[4] C.S. Allardyce, P.J. Dyson, Platinum Metals Rev. 45 (2001) 62–69. 
[5] R.E. Morris, R.E. Aird, P. del Socorro Murdoch, H. Chen, J. Cummings, N.D. Hughes, 
A tetranuclear ruthenium arene complex 
 1
S. Parsons, A. Parkin, G. Boyd, D.I. Jodrell and P.J. Sadler, J. Med. Chem. 44 (2001) 
3616-3621. 
[6] R.E. Aird, A.A. Ritchie, M. Muir, R.E. Morris, H. Chen, P.J. Sadler and D.I. Jodrell, 
Brit. J. Cancer 86 (2002) 1652–1657. 
[7] A.F.A. Peacock, P.J. Sadler, Chem. Asian J. 3 (2008) 1890–1899. 
[8] G. Süss-Fink, Dalton Trans. 39 (2010) 1673–1688. 
[9] C.S. Allardyce, P.J. Dyson, D.J. Ellis, S.L. Heath, Chem. Commun. (2001) 1396–1397. 
[10] W.H. Ang, P.J. Dyson, Eur. J. Inorg. Chem. 20 (2006) 4003–4018. 
[11] P.J. Dyson, Chimia 61 (2007) 698–703. 
[12] S.J. Berners-Price, R.J. Bowen, P.J. Harvey, P.C. Healy, G.A. Koutsantonis, J. Chem. 
Soc., Dalton Trans. (1998) 1743–1750. 
[13] S.J. Berners-Price, R.J. Bowen, T.W. Hambley, P.C. Healy, J. Chem. Soc., Dalton Trans. 
(1999) 1337–1346. 
[14] S.J. Berners-Price, R.J. Bowen, P.C. Healy, Acta Cryst. E60 (2004) o43–o44. 
[15] P.C. Kunz, C. Wetzel, M. Bongartz, A.L. Noffke, B. Spingler, J. Organomet. Chem. 695 
(2010) 1891–1897. 
[16] C. Daguenet, R. Scopelliti, P.J. Dyson, Organometallics 23 (2004) 4849–4857. 
[17] S.W. Magennis, A. Habtemariam, O. Novakova, J.B. Henry, S. Meier, S. Parsons, I.D.H. 
Oswald, V. Brabec, P.J. Sadler, Inorg. Chem. 46 (2007) 5059-5068. 
[18] M. Gras, B. Therrien, G. Süss-Fink, A. Casini, F. Edafe, P.J. Dyson, J. Organomet. 
Chem. 695 (2010) 1119-1125. 
[19] P. Govender, N.C. Antonels, J. Mattsson, A.K. Renfrew, P.J. Dyson, J.R. Moss, B. 
Therrien, G. S. Smith, J. Organomet. Chem. 694 (2009) 3470-3476. 
[20] J. Mattsson, P. Govindaswamy, A.K. Renfrew, P.J. Dyson, P. Stepnicka, G. Süss-Fink, 
B. Therrien, Organometallics 28 (2009) 4350-4357. 
[21] N.P.E. Barry, O. Zava, J. Furrer, P.J. Dyson, B. Therrien, Dalton Trans. 39 (2010) 5272-
5277. 
[22] G.S. Smith and P. Govender, Anticancer Activity of Multinuclear Ruthenium-Arene 
Complexes Coordinated to Dendritic Poly(propylenimine) Scaffolds, oral presentation 
at the 5th International Symposium on Bioorganometallic Chemisty 2010, Book of 
Abstracts p33, http://www.rub.de/isbomc10/gfx/isbomc10_book_of_abstracts.pdf 
[23] T. Mosmann, J. Immunol. Methods 65 (1983) 55–63. 
[24] CrysAlisPro Software system, Oxford Diffraction Ltd, 171.32, Oxford, UK, 2007. 
[25] A. Altomare, M.C. Burla, M. Camalli, G.L. Cascarano, C. Giacovazzo, A. Guagliardi, 
A tetranuclear ruthenium arene complex 
 1
A.G.G. Moliterni, G. Polidori, R. Spagna, J. Appl. Cryst., 32 (1999) 115-119. 
[26] G.M. Sheldrick, Acta Cryst., A64 (2008) 112-122. 
[27] A. Spek, J. Appl. Cryst., 36 (2003) 7-13. 
[28] A.W. Coleman, D.F. Jones, P.H. Dixneuf, C. Brisson, J.J. Bonnet, G. Lavigne, Inorg. 
Chem. 23 (1984) 952–956. 
[29] L. C. Thomas, Interpretation of the Infrared Spectra of Organophosphorus Compounds, 
Heyden &Son Ltd., London, 1974. 
[30] H.E. Howard-Lock, C.J.L. Lock, S. Penny, M. A. Turner, Can. J. Chem. 67 (1989) 
1051-1060. 
[31] J.F. Britten, C.J.L. Lock, Z. Wang, Acta Cryst. C49 (1993) 881-884. 
[32] P.C. Kunz, W. Frank, Acta Cryst. E66 (2010) o1440. 
[33] C. A. Vock, C. Scolaro, A. D. Phillips, R. Scopelliti, G. Sava, P. J. Dyson, J. Med. 
Chem. 49 (2006) 5552–5561. 
[34] F. Marchetti, C. Pettinari, R. Pettinari, A. Cerquetella, C. D. Nicola, A. Macchioni, D. 
Zuccaccia, M. Monari, F. Piccinelli, Inorg. Chem. 47 (2008) 11593–11603. 
[35] M.R.J. Elsegood, M. B. Smith, N. M. Sanchez-Bellester, Acta Cryst. E62 (2006) 
m2838. 
[36] A. Caballero, F. A. Jalon, B. R. Manzano, G. Espino, M. Perez-Manrique, A. Mucientes, 
F. J. Poblete, M. Maestro, Organometallics 23 (2004) 5694–5706. 
 
A tetranuclear ruthenium arene complex 
 1
Electronic supporting information for  
Synthesis, x-ray crystal structure and cytotoxicity of a tetranuclear ruthenium arene 
complex 
Anna Louisa Noffke,[a] Melanie Bongartz,[a] Wim Wätjen,[b]   Bernhard Spingler[c],[‡] and 
Peter C. Kunz*[a] 
[a] Heinrich-Heine-Universität, Institut für Anorganische Chemie und Strukturchemie I, 
Düsseldorf, Universitätsstr. 1, D-40225 Düsseldorf, Germany, Fax: +49 211 811287, Email: 
peter.kunz@uni-duesseldorf.de 
[b] Heinrich-Heine-Universität, Universitätsklinikum, Institut für Toxikologie, Düsseldorf, 
Universitätsstr. 1, D-40225 Düsseldorf, Germany 
[c] Anorganisch-Chemisches Institut, Universität Zürich-Irchel, Winterthurerstr. 190, CH-
8057 Zürich, Switzerland 
[‡] X-ray structure analysis. 
 
Table ESI1.   Bond lengths [Å] and angles [°] for 3·0.8C4H10O.  
Table ESI2.   Bond lengths [Å] and angles [°] for 5·4CH3OH. 
A tetranuclear ruthenium arene complex 
 1
Table ESI1.   Bond lengths [Å] and angles [°] for 3·0.8C4H10O. 
_____________________________________________________
Ru(1)-N(13)  2.072(5) 
Ru(1)-N(18)  2.085(5) 
Ru(1)-C(15)  2.147(13) 
Ru(1)-C(32)  2.153(19) 
Ru(1)-C(33)  2.158(17) 
Ru(1)-C(35)  2.168(18) 
Ru(1)-C(34)  2.18(2) 
Ru(1)-C(12)  2.190(14) 
Ru(1)-C(13)  2.192(14) 
Ru(1)-C(14)  2.200(13) 
Ru(1)-C(36)  2.201(18) 
Ru(1)-C(31)  2.210(18) 
Ru(2)-C(24)  2.195(7) 
Ru(2)-C(22)  2.199(7) 
Ru(2)-C(23)  2.218(8) 
Ru(2)-C(25)  2.225(8) 
Ru(2)-C(21)  2.231(8) 
Ru(2)-C(26)  2.272(8) 
Ru(2)-P(1)  2.3407(19) 
Ru(2)-Cl(3)  2.3822(19) 
Ru(2)-Cl(2)  2.401(2) 
C(1)-C(1)#1  1.531(12) 
C(1)-P(1)  1.858(5) 
C(1)-H(1A)  0.9900 
C(1)-H(1B)  0.9900 
C(2)-N(13)  1.321(8) 
C(2)-N(24)  1.361(8) 
C(2)-P(1)  1.821(7) 
C(3)-C(4)  1.357(10) 
C(3)-N(13)  1.365(8) 
C(3)-H(3A)  0.9500 
C(4)-N(24)  1.361(8) 
C(4)-H(4A)  0.9500 
C(5)-N(24)  1.460(8) 
C(5)-H(5C)  0.9800 
C(5)-H(5B)  0.9800 
C(5)-H(5A)  0.9800 
C(6)-N(18)  1.323(8) 
C(6)-N(23)  1.358(8) 
C(6)-P(1)  1.824(7) 
C(7)-C(8)  1.338(9) 
C(7)-N(18)  1.383(9) 
C(7)-H(7A)  0.9500 
C(8)-N(23)  1.374(9) 
C(8)-H(8A)  0.9500 
C(9)-N(23)  1.451(8) 
C(9)-H(9C)  0.9800 
C(9)-H(9B)  0.9800 
C(9)-H(9A)  0.9800 
C(10)-C(11)  1.551(19) 
C(10)-H(10C)  0.9800 
C(10)-H(10B)  0.9800 
C(10)-H(10A)  0.9800 
C(11)-C(12)  1.33(2) 
C(11)-C(13)  1.373(18) 
C(12)-C(14)  1.45(2) 
C(12)-H(12A)  0.9500 
C(13)-C(15)  1.379(19) 
C(13)-H(13A)  0.9500 
C(14)-C(16)  1.443(18) 
C(14)-H(14A)  0.9500 
C(15)-C(16)  1.41(2) 
C(15)-H(15A)  0.9500 
C(16)-C(17)  1.50(2) 
C(17)-C(18)  1.41(3) 
C(17)-C(19)  1.62(2) 
C(17)-H(17)  1.0000 
C(18)-H(18A)  0.9800 
C(18)-H(18B)  0.9800 
C(18)-H(18C)  0.9800 
C(19)-H(19A)  0.9800 
C(19)-H(19B)  0.9800 
C(19)-H(19C)  0.9800 
C(30)-C(31)  1.53(3) 
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C(30)-H(30A)  0.9800 
C(30)-H(30B)  0.9800 
C(30)-H(30C)  0.9800 
C(31)-C(32)  1.44(3) 
C(31)-C(33)  1.51(2) 
C(32)-C(34)  1.36(3) 
C(32)-H(32A)  0.9500 
C(33)-C(35)  1.43(2) 
C(33)-H(33A)  0.9500 
C(34)-C(36)  1.38(3) 
C(34)-H(34A)  0.9500 
C(35)-C(36)  1.43(3) 
C(35)-H(35A)  0.9500 
C(36)-C(37)  1.48(3) 
C(37)-C(38)  1.50(3) 
C(37)-C(39)  1.531(9) 
C(37)-H(37)  1.0000 
C(38)-H(38A)  0.9800 
C(38)-H(38B)  0.9800 
C(38)-H(38C)  0.9800 
C(39)-H(39C)  0.9800 
C(39)-H(39B)  0.9800 
C(39)-H(39A)  0.9800 
O(41)-C(43)  1.36(3) 
O(41)-C(42)  1.47(3) 
C(41)-C(42)  1.46(3) 
C(41)-H(41A)  0.9800 
C(41)-H(41B)  0.9800 
C(41)-H(41C)  0.9800 
C(42)-H(42A)  0.9900 
C(42)-H(42B)  0.9900 
C(43)-C(44)  1.527(10) 
C(43)-H(43A)  0.9900 
C(43)-H(43B)  0.9900 
C(44)-H(44A)  0.9800 
C(44)-H(44B)  0.9800 
C(44)-H(44C)  0.9800 
C(20)-C(21)  1.520(12) 
C(20)-H(20A)  0.9800 
C(20)-H(20B)  0.9800 
C(20)-H(20C)  0.9800 
C(21)-C(22)  1.382(11) 
C(21)-C(23)  1.398(12) 
C(22)-C(24)  1.418(10) 
C(22)-H(22A)  0.9500 
C(23)-C(25)  1.345(12) 
C(23)-H(23A)  0.9500 
C(24)-C(26)  1.400(10) 
C(24)-H(24A)  0.9500 
C(25)-C(26)  1.453(11) 
C(25)-H(25A)  0.9500 
C(26)-C(27)  1.490(11) 
C(27)-C(28)  1.522(11) 
C(27)-C(29)  1.540(11) 
C(27)-H(27)  1.0000 
C(28)-H(28A)  0.9800 
C(28)-H(28B)  0.9800 
C(28)-H(28C)  0.9800 
C(29)-H(29A)  0.9800 
C(29)-H(29B)  0.9800 
C(29)-H(29C)  0.9800
 





















































































































































































































































































































































































Symmetry transformations used to generate equivalent atoms:  
#1 -x+1,y,-z+3/2      
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Table ESI2.   Bond lengths [Å] and angles [°] for 5·4CH3OH. 
_____________________________________________________
Ru(1)-N(3)  2.0927(9) 
Ru(1)-N(1)  2.1058(9) 
Ru(1)-C(13)  2.1779(12) 
Ru(1)-C(12)  2.1846(11) 
Ru(1)-C(14)  2.1889(11) 
Ru(1)-C(15)  2.2063(11) 
Ru(1)-C(11)  2.2239(12) 
Ru(1)-C(16)  2.2450(11) 
Ru(1)-Cl(1)  2.3921(3) 
C(1)-C(1)#1  1.530(2) 
C(1)-P(1)  1.7884(11) 
C(1)-H(1A)  0.9900 
C(1)-H(1B)  0.9900 
C(2)-N(1)  1.3359(13) 
C(2)-N(2)  1.3583(13) 
C(2)-P(1)  1.7944(10) 
C(3)-C(4)  1.3617(17) 
C(3)-N(1)  1.3718(14) 
C(3)-H(3A)  0.9500 
C(4)-N(2)  1.3672(15) 
C(4)-H(4A)  0.9500 
C(5)-N(2)  1.4630(15) 
C(5)-H(5C)  0.9800 
C(5)-H(5B)  0.9800 
C(5)-H(5A)  0.9800 
C(6)-N(3)  1.3403(13) 
C(6)-N(4)  1.3577(14) 
C(6)-P(1)  1.8059(11) 
C(7)-C(8)  1.3650(17) 
C(7)-N(3)  1.3727(14) 
C(7)-H(7A)  0.9500 
C(8)-N(4)  1.3656(16) 
C(8)-H(8A)  0.9500 
C(9)-N(4)  1.4687(16) 
C(9)-H(9A)  0.9800 
C(9)-H(9B)  0.9800 
C(9)-H(9C)  0.9800 
C(10)-C(11)  1.5000(19) 
C(10)-H(10C)  0.9800 
C(10)-H(10B)  0.9800 
C(10)-H(10A)  0.9800 
C(11)-C(12)  1.4064(19) 
C(11)-C(13)  1.4280(18) 
C(12)-C(14)  1.4300(19) 
C(12)-H(12A)  0.9500 
C(13)-C(15)  1.4121(17) 
C(13)-H(13A)  0.9500 
C(14)-C(16)  1.4087(17) 
C(14)-H(14A)  0.9500 
C(15)-C(16)  1.4294(16) 
C(15)-H(15A)  0.9500 
C(16)-C(17)  1.5145(18) 
C(17)-C(19)  1.527(2) 
C(17)-C(18)  1.547(2) 
C(17)-H(17)  1.0000 
C(18)-H(18A)  0.9800 
C(18)-H(18B)  0.9800 
C(18)-H(18C)  0.9800 
C(19)-H(19A)  0.9800 
C(19)-H(19C)  0.9800 
C(19)-H(19B)  0.9800 
C(31)-O(31)  1.302(5) 
C(31)-O(31B)  1.419(6) 
O(1)-P(1)  1.4795(9) 
C(32)-O(32)  1.401(4) 
C(32)-O(32B)  1.447(5)
 








































































































































































Symmetry transformations used to generate equivalent atoms:   
#1 -x+1,-y+1,-z+1      
